Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sarepta Therapeutics Off To A Strong Start With New Name And Data

This article was originally published in The Pink Sheet Daily

Executive Summary

The RNA drug-discovery company, formerly AVI BioPharma, is reinventing itself as an orphan disease drug specialist called Sarepta Therapeutics. With the release of positive Phase IIb data on its lead candidate for Duchenne muscular dystrophy, the transformation has gotten a big boost.

You may also be interested in...

Financings Of The Fortnight: Life Science Venture Funding Not Necessarily On The Decline

Plus news on recent financings by Foundation Medicine, Ultragenyx, Labrys Biologics, Solstice Biologics and Sarepta Therapeutics.

$118 Million Offering Should Position Sarepta Strongly For Partnering Talks

As the Duchenne muscular dystrophy-focused biotech raises significant cash from institutional investors, CEO clarifies that Sarepta is intent on finding the right partner, structure and economics for an ex-North American opportunity.

GlaxoSmithKline in a Rare-Disease Pact with Prosensa for RNA-modulation Drugs

GSK is paying £16m ($25m) upfront for rights to Prosensa's lead Duchenne's compound, and takes hallmark options to related candidates.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts